Infliximab and Etanercept Biosimilars and Originators: Learnings from Regional Market Dynamics in Germany


Barcina T1, Moorkens E2, Vulto A3, Schulz M4, Gradl G5, Enners S5, Selke G6, Huys I2, Simoens S2
1KU Leuven, Leuven, VBR, Belgium, 2KU Leuven, Leuven, Belgium, 3The Erasmus University Medical Center, Rotterdam, Netherlands, 4ABDA- Federal Union of German Associations of Pharmacists, Berlin, Germany, 5DAPI - German Institute for Drug Use Evaluation, Berlin, Germany, 6WidO - AOK Research Institute, Berlin, Germany

OBJECTIVES : This study aims to examine how several factors, especially regional-level differences in policy measures and practices, influence market dynamics of infliximab and etanercept biosimilars and originators in Germany.

METHODS : First, a literature review was conducted on (biosimilar) policies in Germany. Second, regional dispensing data were analysed using the database of the German Institute for Drug Use Evaluation (DAPI) with respect to TNFα inhibitor originators and biosimilars (Q1 2010 to Q4 2018). Third, ten semi-structured interviews were conducted to investigate prescribers’ and insurers’ views at the national and regional level.

RESULTS : The analysis of biosimilar market shares of infliximab and etanercept across Germany’s 17 regions of the Regional Association of Statutory Health Insurance Accredited Physicians revealed wide variations. Similar uptake patterns were described for infliximab and etanercept biosimilars, allowing to identify common low- and high-uptake regions. Sachsen, Sachsen-Anhalt, Brandenburg, Berlin and Baden-Württemberg showed low uptake for both infliximab and etanercept biosimilars. Niedersachsen, Westfalen-Lippe, Bayern and Nordrhein showed high uptake for both infliximab and etanercept biosimilars. Quantitative analysis indicated that 36% (p ≤ 0.05) and 39% (p ≤ 0.05) of the variability in biosimilar market shares for infliximab and etanercept, respectively, could be explained by the East/West location of the regions. In addition, qualitative interview analysis illustrated that the use of biosimilars may depend on: (1) the regional-level implementation of biosimilar quotas and the presence of monitoring/sanctioning mechanisms which ensure adherence to these quotas, (2) the different insurer-manufacturer discount contracts established at the regional level, and (3) the organization of initiatives for gainsharing at the insurer-prescriber level.

CONCLUSIONS : Uptake of biosimilars in Germany is region specific and is driven by a complex interplay of factors. This study has emphasized the role of prescription and drug budget control activities in driving variable biosimilar uptake for infliximab and etanercept across Germany.

Conference/Value in Health Info

2020-11, ISPOR Europe 2020, Milan, Italy

Value in Health, Volume 23, Issue S2 (December 2020)




Health Policy & Regulatory, Health Service Delivery & Process of Care

Topic Subcategory

Prescribing Behavior, Procurement Systems


Biologics and Biosimilars, Systemic Disorders/Conditions

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on Update my browser now